Dr. Scholl’s Arthritis, Diabetes Claims Supported By Data – NAD
This article was originally published in The Tan Sheet
Executive Summary
Diabetes and arthritis claims made on labeling and in advertisements for Dr. Scholl's StepWell Insoles are substantiated by clinical studies conducted by marketer Schering-Plough, the National Advertising Division of the Council of Better Business Bureaus determines in a recently released Case Report
You may also be interested in...
McNeil St. Joseph “Aspirin Therapy” Claim Needs Refining, NAD Says
McNeil Consumer & Specialty Pharmaceuticals should more narrowly target future advertising claims for St. Joseph Adult Low-Strength Aspirin "to avoid the risk of inaccurately communicating that 81 mg is the appropriate and recommended dosage for all types of 'aspirin therapy,'" the National Advertising Division says
McNeil St. Joseph “Aspirin Therapy” Claim Needs Refining, NAD Says
McNeil Consumer & Specialty Pharmaceuticals should more narrowly target future advertising claims for St. Joseph Adult Low-Strength Aspirin "to avoid the risk of inaccurately communicating that 81 mg is the appropriate and recommended dosage for all types of 'aspirin therapy,'" the National Advertising Division says
McNeil St. Joseph “Aspirin Therapy” Claim Needs Refining, NAD Says
McNeil Consumer & Specialty Pharmaceuticals should more narrowly target future advertising claims for St. Joseph Adult Low-Strength Aspirin "to avoid the risk of inaccurately communicating that 81 mg is the appropriate and recommended dosage for all types of 'aspirin therapy,'" the National Advertising Division says